Certain A Shares of Shanghai ZJ Bio-Tech Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2024.
January 18, 2024
Share
Certain A Shares of Shanghai ZJ Bio-Tech Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2024. These A Shares will be under lockup for 1102 days starting from 12-JAN-2021 to 19-JAN-2024.
Details:
The company?s holding shareholder Shanghai Zhijiang Pharmaceutical Co., Ltd. and actual controller Shao Junbin, Ningbo Kangfei Dunsi Investment Management Partnership Enterprise (Limited Partnership), close relatives of actual controller Shao Junjie, Shao Yanfen, agreed not to transfer any shares within 36 months after the listing date.
If the closing price of the company?s share is lower than the issue price for 20 consecutive trading days within 6 months after listing, or if the closing price of the company?s share is lower than the issue price for the period ending six months after listing, then the lockup period will automatically be extended for at least 6 months.
The company?s director Ni Weiqin, supervisor Ji Chengwei, Wang Yiyun, deputy general manager Ma Jingming, deputy general manager Wang Kai, company?s core technical personnel Zhang Jie, Zhu Qinwei, Li Peixiao, Shu Feng, Liu Yan, supervisor Wang Yueming?s son Wang Neng, and shareholder Zhongxin (Shanghai) Equity Investment Center (Limited Partnership), Shanghai Nengfa Invesmtent Consulting Co., Ltd, Ningbo Ruidao Investment Management Partnership Enterprise (Limited Partnership), and other shareholders agreed not to transfer any shares within 12 months after the listing date.
Shanghai ZJ Bio-Tech Co Ltd is a China-based company that mainly engaged in the production of molecular diagnostic reagents. The Company is mainly engaged in the research, development, production and sales of genetic diagnostic reagents and equipment. The Company's main products include nucleic acid detection kits and molecular diagnostic instruments. The Company's products are mainly used in areas such as emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. The Company mainly conducts business within the domestic market.